Literature DB >> 8381656

Growth arrest of the breast cancer cell line, T47D, by TNF alpha; cell cycle specificity and signal transduction.

L Pusztai1, C E Lewis, J O McGee.   

Abstract

The effects of tumour necrosis factor-alpha (TNF alpha) on the growth and DNA synthesis of the human breast cell line, T47D, were studied. A dose-dependent, reversible inhibition of thymidine incorporation and cell growth was observed in the range of 0.1 ng ml-1 to 100 ng ml-1 of TNF alpha. Cell viability was not impaired in any of the experiments. Flow-cytometric DNA analysis demonstrated that after 24 h exposure to TNF alpha, T47D cells accumulated in the G1 phase of the cell cycle, and were depleted in the G2/M and S phases, suggesting a block in the progression of the G1/S transition. The involvement of protein kinases (PK) and protein phosphatases in TNF alpha-induced signal transduction was also investigated. A transient and rapid 2-fold increase in total cellular protein kinase C (PKC) activity was detected after 10 min exposure to TNF alpha. To study the role of the observed PKC activation in the cytostatic effect of TNF alpha, T47D cells were exposed to the cytokine in the presence of the potent PKC inhibitor, H7. The inhibitory effect of TNF alpha on thymidine incorporation was not affected by exposure to H7 at concentrations sufficient to block the stimulation of thymidine up-take induced by the PKC agonist, phorbol-12-myristate-13-acetate (PMA). The involvement of other signalling pathways was addressed using the cyclic nucleotide-dependent PK inhibitor, H8; the calmodulin-dependent PK inhibitor, W7; and the inhibitor of protein phosphatases PP1 and PP2B, okadaic acid. Exposure of T47D cells to these enzyme inhibitors failed to antagonise the inhibition of thymidine incorporation by TNF alpha. Taken together, these results indicate that the cytostatic effect of TNF alpha on T47D cells occurs at the G1/S transition of the cell cycle, and is mediated by an intracellular pathway which does not involve the activity of protein kinases C and A, nor protein phosphatases PP1, PP2B.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8381656      PMCID: PMC1968192          DOI: 10.1038/bjc.1993.55

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  36 in total

1.  Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines.

Authors:  L Fransen; J Van der Heyden; R Ruysschaert; W Fiers
Journal:  Eur J Cancer Clin Oncol       Date:  1986-04

2.  Lymphocyte proliferation and cytotoxic assays using flat-bed scintillation counting.

Authors:  C G Potter; F Gotch; G T Warner; J Oestrup
Journal:  J Immunol Methods       Date:  1987-12-24       Impact factor: 2.303

3.  A rapid single step staining technique for DNA analysis by flow microfluorimetry.

Authors:  I W Taylor
Journal:  J Histochem Cytochem       Date:  1980-09       Impact factor: 2.479

4.  Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells.

Authors:  V Ruggiero; K Latham; C Baglioni
Journal:  J Immunol       Date:  1987-04-15       Impact factor: 5.422

5.  The effect of recombinant human tumour necrosis factor on growth and macromolecular synthesis of human epithelial cells.

Authors:  G B Dealtry; M S Naylor; W Fiers; F R Balkwill
Journal:  Exp Cell Res       Date:  1987-06       Impact factor: 3.905

6.  NF-kappa B activation by tumor necrosis factor alpha in the Jurkat T cell line is independent of protein kinase A, protein kinase C, and Ca(2+)-regulated kinases.

Authors:  J Feuillard; H Gouy; G Bismuth; L M Lee; P Debré; M Körner
Journal:  Cytokine       Date:  1991-05       Impact factor: 3.861

7.  Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C.

Authors:  H Hidaka; M Inagaki; S Kawamoto; Y Sasaki
Journal:  Biochemistry       Date:  1984-10-09       Impact factor: 3.162

8.  Cell cycle-specific effects of tumor necrosis factor.

Authors:  Z Darzynkiewicz; B Williamson; E A Carswell; L J Old
Journal:  Cancer Res       Date:  1984-01       Impact factor: 12.701

9.  Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro.

Authors:  B J Sugarman; B B Aggarwal; P E Hass; I S Figari; M A Palladino; H M Shepard
Journal:  Science       Date:  1985-11-22       Impact factor: 47.728

10.  Rapid phosphorylation of a 27 kDa protein induced by tumor necrosis factor.

Authors:  A Hepburn; D Demolle; J m Boeynaems; W Fiers; J E Dumont
Journal:  FEBS Lett       Date:  1988-01-25       Impact factor: 4.124

View more
  10 in total

1.  Identification and characterization of unique tumoricidal genes in rat umbilical cord matrix stem cells.

Authors:  Deepthi Uppalapati; Naomi Ohta; Yongqing Zhang; Atsushi Kawabata; Marla M Pyle; Kevin G Becker; Deryl Troyer; Masaaki Tamura
Journal:  Mol Pharm       Date:  2011-09-13       Impact factor: 4.939

2.  Distinct pathways for tumor necrosis factor alpha and ceramides in human cytomegalovirus infection.

Authors:  J Allan-Yorke; M Record; C de Préval; C Davrinche; J L Davignon
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

3.  Calcium- and integrin-binding protein 1 regulates microtubule organization and centrosome segregation through polo like kinase 3 during cell cycle progression.

Authors:  Meghna U Naik; Ulhas P Naik
Journal:  Int J Biochem Cell Biol       Date:  2010-10-15       Impact factor: 5.085

Review 4.  A multi-targeted approach to suppress tumor-promoting inflammation.

Authors:  Abbas K Samadi; Alan Bilsland; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Anupam Bishayee; Asfar S Azmi; Bal L Lokeshwar; Brendan Grue; Carolina Panis; Chandra S Boosani; Deepak Poudyal; Diana M Stafforini; Dipita Bhakta; Elena Niccolai; Gunjan Guha; H P Vasantha Rupasinghe; Hiromasa Fujii; Kanya Honoki; Kapil Mehta; Katia Aquilano; Leroy Lowe; Lorne J Hofseth; Luigi Ricciardiello; Maria Rosa Ciriolo; Neetu Singh; Richard L Whelan; Rupesh Chaturvedi; S Salman Ashraf; H M C Shantha Kumara; Somaira Nowsheen; Sulma I Mohammed; W Nicol Keith; William G Helferich; Xujuan Yang
Journal:  Semin Cancer Biol       Date:  2015-05-05       Impact factor: 15.707

5.  Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model.

Authors:  Tiphanie Durfort; Mercedes Tkach; Mariya I Meschaninova; Martín A Rivas; Patricia V Elizalde; Alya G Venyaminova; Roxana Schillaci; Jean-Christophe François
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

6.  Expression of tumor necrosis factor-alpha and interleukin-6 in oral squamous cell carcinoma.

Authors:  Y Nakano; W Kobayashi; S Sugai; H Kimura; S Yagihashi
Journal:  Jpn J Cancer Res       Date:  1999-08

7.  Human Amniotic Epithelial Cells and Their Derived Exosomes Protect Against Cisplatin-Induced Acute Kidney Injury Without Compromising Its Antitumor Activity in Mice.

Authors:  Xin Kang; Ying Chen; Xiaohong Xin; Menghan Liu; Yuan Ma; Yifei Ren; Jing Ji; Qi Yu; Lei Qu; Suxia Wang; Gang Liu; Chengang Xiang; Li Yang
Journal:  Front Cell Dev Biol       Date:  2022-02-03

8.  Growth inhibition in clonal subpopulations of a human epithelioid sarcoma cell line by retinoic acid and tumour necrosis factor alpha.

Authors:  R Engers; F van Roy; T Heymer; U Ramp; R Moll; M Dienst; U Friebe; A Pohl; H E Gabbert; C D Gerharz
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

9.  Dipyridamole combined with tumor necrosis factor-alpha enhances inhibition of proliferation in human tumor cell lines.

Authors:  N Suzuki; S Sekiya; I Sugano; T Kojima; H Yamamori; Y Takakubo
Journal:  Jpn J Cancer Res       Date:  1995-08

Review 10.  Innate Immune Defense Mechanisms by Myeloid Cells That Hamper Cancer Immunotherapy.

Authors:  Els Lebegge; Sana M Arnouk; Pauline M R Bardet; Máté Kiss; Geert Raes; Jo A Van Ginderachter
Journal:  Front Immunol       Date:  2020-07-09       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.